Pfizer (NYSE: PFE) and Astellas (NASDAQOTH: ALPMY) share profit on the blockbuster prostate cancer drug Xtandi, and AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) split profit on the blockbuster lymphoma and leukemia drug Imbruvica. However, these companies took very different paths to adding these drugs to their portfolios.